Exploiting Tumour Hypoxia in Precision Medicine: Advancing Novel Prodrug Therapies for Pancreatic Cancer with a World-leading Canadian Cancer Centre

点击翻译按钮获取中文摘要

The effectiveness of cancer therapy can be limited by barriers to drug penetration at the tumour and theharbouring of drug-resistant cells in poorly oxygenated or "hypoxic" tumour regions - these becomingsources of spread. The UK company Oncotherics has developed non-toxic drugs that are designed topenetrate into these difficult to treat regions, sense the low levels of oxygen and “activate” to kill theproblematic cancer cells. The challenge is highlighted by the treament resistance of pancreatic cancer withonly 1 in every 100 patients in England & Wales surviving their disease for more than 10 years with littleimprovment since the 1970s. Our key innovation is to link with a world-leading Cancer Centre in Canadato approach a clincal trial that exploits a ground-breaking imaging technology that will allow us to identifypancreatic cancer patients with hypoxic tumours for this targeted drug therapy. Funding will acceleratethis link with PMCC , increase the prospects for investor interest with entry into a $1.7bn global market,provide a route to regulatory approval and clinical adoption in cancer centres both in the UK & globally.